Upstream Bio (UPB) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vogenx is the larger company by market cap ($263.6 million vs $249.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UPB | VOGX |
|---|---|---|
| Share price | $4.56 | $17.75 |
| Market cap | $249.76M | $263.60M |
| 1-day change | -1.08% | +9.81% |
| YTD return | -83.02% | — |
| 1-year return | -75.31% | — |
| EPS (TTM) | $-2.88 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.68 | $38.41 |
| 52-week low | $4.37 | $12.95 |
| Distance from 52-week high | -86.46% | -53.80% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +582.89% | +209.95% |
| Average volume | 610.08K | 188.79K |
| Shares outstanding | 54.77M | 14.86M |
| Employees | 75 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
UPB vs VOGX FAQ
Which is bigger, Upstream Bio or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $263.60M compared with $249.76M for Upstream Bio (UPB).
Are Upstream Bio and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.